Quarterly report pursuant to Section 13 or 15(d)

Equity (Tables)

v3.22.1
Equity (Tables)
 9 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of sales through equity offering program
Three months ended   Avg price
per share		     Number of
Shares		     Gross
Proceeds
(in millions)		     Offering
Expenses
(in millions)		     Net
Proceeds
(in millions)		  
September 30, 2021   $ 9.99       555,455     $ 5.5     $ 0.1     $ 5.4  
December 31, 2021   $ 7.04       1,931,022     $ 13.6     $ 0.2     $ 13.4  
March 31, 2022   $ 6.03       1,157,919     $ 7.0     $ 0.2     $ 6.8  
Total   $ 7.17       3,644,396     $ 26.1     $ 0.5     $ 25.6  

 
Schedule of black-scholes option pricing model with weighted average assumptions
    Nine Months
Ended
March 31,
2022		  
Exercise price   $  5.63 – 10.15  
Expected term (years)     4.75 – 5.00  
Volatility     66-67 %
Risk-free interest rate     0.76% – 2.18 %
Dividend yield     0 %
Weighted Average Grant Date Fair Value of Options granted during the period   $ 4.94  

  
Schedule of stock-based compensation expense
    Three Months Ended
March 31,		     Nine Months Ended
March 31,		  
    2022     2021     2022     2021  
Research and Development   $ 1,327     $ 1,011     $ 4,275     $ 2,953  
General and Administrative     1,179       980       3,479       3,131  
Total   $ 2,506     $ 1,991     $ 7,754     $ 6,084  

 
Schedule of unrecognized stock-based compensation expense and weighted-average years
    As of March 31, 2022  
    Unrecognized
stock-based
compensation		     Weighted-
average years
to be recognized		  
Options   $ 3,714       2.47  
Restricted stock units   $ 10,788       2.30